中国化学快报(英文版)2024，Vol.35Issue(2) ：436-440.DOI:10.1016/j.cclet.2023.108466

Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells

Guizhen Zhu Yaoyao Zhao Wenmei Zhang Yuanyuan Wu Yuanxing Liu Guangsheng Guo Xiayan Wang Zhihong Liu
中国化学快报(英文版)2024，Vol.35Issue(2) ：436-440.DOI:10.1016/j.cclet.2023.108466
✕
  • 维普
  • 万方数据

Single-cell mass spectrometry studies of drug metabolism heterogeneity and primary resistance to gefitinib in non-small cell lung cancer cells

Guizhen Zhu 1Yaoyao Zhao 1Wenmei Zhang 1Yuanyuan Wu 1Yuanxing Liu 1Guangsheng Guo 2Xiayan Wang 1Zhihong Liu3
扫码查看

作者信息

  • 1. Center of Excellence for Environmental Safety and Biological Effects,Beijing Key Laboratory for Green Catalysis and Separation,Department of Chemistry,Beijing University of Technology,Beijing 100124,China
  • 2. Center of Excellence for Environmental Safety and Biological Effects,Beijing Key Laboratory for Green Catalysis and Separation,Department of Chemistry,Beijing University of Technology,Beijing 100124,China;Minzu University of China,Beijing 100081,China
  • 3. Key Laboratory for the Synthesis and Application of Organic Functional Molecules,College of Health Science and Engineering,Hubei University,Wuhan 430062,China
  • 折叠

Abstract

Patients with epidermal growth factor receptor(EGFR)wild-type non-small cell lung cancer(NSCLC)of-ten show primary resistance to gefitinib therapy.It is thus necessary to study the metabolism of gefitinib in NSCLC cells to comprehensively reveal the reasons for the primary resistance of tumors.Herein,we develop a platform for studying drug metabolism heterogeneity based on single-cell mass spectrometry(sDMH-scMS)by integrating living-cell electrolaunching ionization MS(ILCEI-MS)and high-performance liquid chromatography-MS(HPLC-MS)analysis,and the primary resistance of NSCLC cells to gefitinib was studied using this platform.The ILCEI-MS analysis showed that approximately 11.9％of NSCLC single cells contained the gefitinib metabolite M11;HPLC-MS detection diluted the intensity of M11 in subpopula-tions and concealed the heterogeneity of drug metabolism in tumor single cells.The intensity of gefitinib in EGFR wild-type A549 cells was markedly lower than in mutant PC9 cells,and the intensity of gefitinib metabolites was significantly higher than in PC9 cells,suggesting that the primary resistance of NSCLC cells is related to gefitinib metabolism.Moreover,the combination of gefitinib and the drug-metabolizing enzyme inhibitor α-naphthoflavone was shown to overcome the primary resistance of the NSCLC cells.Overall,the results of this study are expected to be applicable for clinical drug resistance diagnosis and treatment at the single-cell level.

Key words

Single-cell mass spectrometry/Drug metabolism/Non-small cell lung cancer/Gefitinib/Primary resistance

引用本文复制引用

基金项目

Beijing Outstanding Young Scientist Program(BJJWZYJH01201910005017)

国家自然科学基金(22127805)

国家自然科学基金(22206008)

出版年

2024
中国化学快报(英文版)
中国化学会

中国化学快报(英文版)

CSTPCDCSCD
影响因子：0.771
ISSN：1001-8417
参考文献量38
段落导航相关论文